Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Virology Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for DDX5 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DDX5 Recombinant Protein (Full-Length / Helicase Domain) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for ATPase and RNA-binding assays. |
View DDX5 Products |
| Gene Delivery | DDX5 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression validation. |
View DDX5 Products |
| Benchmark Ab | Anti-DDX5 Recombinant Antibody High-affinity sequence-verified positive control for Western Blot, IHC, and IP. |
View DDX5 Products |
| Validator | DDX5 siRNA Set Target-specific knockdown pool for functional assay validation. |
View DDX5 Products |
| Related Target A | DDX17 (p72) Highly homologous family member. Essential for counter-screening and selectivity profiling. |
View DDX17 Products |
| Related Target B | CTNNB1 (Beta-Catenin) Key signaling partner; DDX5 acts as a co-activator of Wnt/beta-catenin transcription. |
View CTNNB1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| ATPase Assay Background Noise | E. coli/Sf9 expressed DDX5 with >95% purity to eliminate host ATPase contamination. |
| Subfamily Off-Target Screening | DDX17 and other DEAD-box family homolog panels available for precise selectivity profiling. |
| Lack of Reliable Controls | Sequence-verified clinical benchmark antibodies and positive control expression vectors. |
| False Positive Knockdown | Multi-sequence pooled siRNA sets ensuring high knockdown efficiency with minimal off-target effects. |
Live DDX5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for DDX5 therapeutics is intensifying, with major players shifting focus from traditional genetic knockdown to small-molecule inhibitors and PROTACs (Proteolysis Targeting Chimeras). As first-generation small molecules targeting the ATP-binding pocket reach preclinical milestones, the next wave of R&D is targeting allosteric sites and protein-protein interactions (such as the DDX5-RORγt or DDX5-β-catenin interfaces) to improve selectivity and therapeutic index in solid tumors and viral infections.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic/Biotech Consortia | Colorectal Cancer, Breast Cancer, Glioma | Enzymatic Selectivity Assay (Need high-purity WT and mutant DDX5 vs DDX17) |
| PROTAC / Degraders | Targeted Protein Degradation Pioneers | Prostate Cancer, Hematological Malignancies | Ubiquitination and Degradation Kinetics (Need Lentivirus for stable reporter lines) |
| Antiviral Therapeutics | Infectious Disease Institutes | HBV, SARS-CoV-2, Influenza | RNA-Binding Inhibition Assays (Need sequence-verified, high-purity protein) |